OBJECTIVE: To investigate the relation between the severity of pulmonary hypertension and the outcome of medical treatment. METHODS: 98 patients with primary pulmonary hypertension--nine (6%) with systemic disease and pulmonary hypertension and 39 (27%) with thromboembolic pulmonary hypertension--received medical treatment and were followed between 1982 and 1995. They were given long term intravenous prostaglandin treatment (either epoprostenol (n = 61) or iloprost (n = 13)) or conventional treatment with oral anticoagulants (n = 24) with or without calcium channel blockers. Event-free survival was measured to death or transplant surgery, or pulmonary thromboendarterectomy. RESULTS: Prognosis (hazard ratio) was affected by: New York Heart Association grade, 1.52 (95% confidence interval 1.11 to 2.09); mixed venous oxygen saturation (SvO2%), 0.97 (0.95 to 0.98); cardiac index, 0.72 (0.49 to 1.06); mean right atrial pressure, 1.04 (1.01 to 1.07); and pulmonary vascular resistance, 1.02 (1.00 to 1.04). The median event-free survival time of patients with SvO2 < 60% was 239 days (0 to 502) on conventional treatment (n = 22) and 585 days (300 to 870) on prostaglandin treatment (n = 42). No difference was seen in patients with SvO2 > or = 60% between conventional treatment and prostaglandin treatment, survival being 1275 days (732 to 1818; (n = 48)) and 986 days (541 to 1431; n = 30)), respectively. Capacity for pulmonary vasodilatation did not predict outcome of treatment. CONCLUSIONS: Continuous intravenous prostaglandins were more effective than anticoagulants, with or without calcium channel blockers, in prolonging survival in patients with right heart failure. In these patients a capacity to vasodilate did not predict outcome from medical treatment.
OBJECTIVE: To investigate the relation between the severity of pulmonary hypertension and the outcome of medical treatment. METHODS: 98 patients with primary pulmonary hypertension--nine (6%) with systemic disease and pulmonary hypertension and 39 (27%) with thromboembolic pulmonary hypertension--received medical treatment and were followed between 1982 and 1995. They were given long term intravenous prostaglandin treatment (either epoprostenol (n = 61) or iloprost (n = 13)) or conventional treatment with oral anticoagulants (n = 24) with or without calcium channel blockers. Event-free survival was measured to death or transplant surgery, or pulmonary thromboendarterectomy. RESULTS: Prognosis (hazard ratio) was affected by: New York Heart Association grade, 1.52 (95% confidence interval 1.11 to 2.09); mixed venous oxygen saturation (SvO2%), 0.97 (0.95 to 0.98); cardiac index, 0.72 (0.49 to 1.06); mean right atrial pressure, 1.04 (1.01 to 1.07); and pulmonary vascular resistance, 1.02 (1.00 to 1.04). The median event-free survival time of patients with SvO2 < 60% was 239 days (0 to 502) on conventional treatment (n = 22) and 585 days (300 to 870) on prostaglandin treatment (n = 42). No difference was seen in patients with SvO2 > or = 60% between conventional treatment and prostaglandin treatment, survival being 1275 days (732 to 1818; (n = 48)) and 986 days (541 to 1431; n = 30)), respectively. Capacity for pulmonary vasodilatation did not predict outcome of treatment. CONCLUSIONS: Continuous intravenous prostaglandins were more effective than anticoagulants, with or without calcium channel blockers, in prolonging survival in patients with right heart failure. In these patients a capacity to vasodilate did not predict outcome from medical treatment.
Authors: G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis Journal: Ann Intern Med Date: 1991-09-01 Impact factor: 25.391
Authors: K D Dawkins; S W Jamieson; S A Hunt; J C Baldwin; C M Burke; A Morris; M E Billingham; J Theodore; P E Oyer; E B Stinson Journal: Circulation Date: 1985-05 Impact factor: 29.690
Authors: R Ziesche; V Petkov; K Wittmann; J Kopatschka; L Stiebellehner; P Schenk; P Germann; G Röder; R Ullrich; L H Block Journal: Heart Date: 2000-04 Impact factor: 5.994
Authors: Ralf Ewert; Christian F Opitz; Roland Wensel; Jörg Winkler; Michael Halank; Stephan B Felix Journal: Clin Res Cardiol Date: 2007-02-15 Impact factor: 5.460
Authors: N Nagaya; Y Shimizu; T Satoh; H Oya; M Uematsu; S Kyotani; F Sakamaki; N Sato; N Nakanishi; K Miyatake Journal: Heart Date: 2002-04 Impact factor: 5.994
Authors: Jennifer Lee; Pedro M Moraes-Vieira; Angela Castoldi; Pratik Aryal; Eric U Yee; Christopher Vickers; Oren Parnas; Cynthia J Donaldson; Alan Saghatelian; Barbara B Kahn Journal: J Biol Chem Date: 2016-08-29 Impact factor: 5.157